8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 23, 2026·SEC
Material company update
Feb 26, 2026·SEC
Tectonic Therapeutic, Inc.(TECX)Earnings, Financials & Key Ratios
TECX•NASDAQ
$31.99
Price updated Jun 27, 2026
AboutTectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.Show more
- Revenue$0
- EBITDA-$83M-46.6%
- Net Income-$74M-27.9%
- EPS (Diluted)-4.05-3.1%
- ROE-37.82%+81.7%
TECX Price & Volume
Tectonic Therapeutic, Inc. (TECX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Drive Sustained Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial Position:Healthy
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
"Tectonic Therapeutic is currently in a high-stakes clinical development phase, characterized by an aggressive expansion of R&D spending to advance its GEODe platform and RXFP1 agonist program. While the company maintains a robust liquidity position with $236.9 million in cash, the lack of revenue generation and persistent operating losses of $27.3 million in 2026Q1 necessitate careful monitoring of clinical milestones. Investors should remain cautious regarding potential future dilution, as the company relies on external capital to fund its asset-light, outsourced operational model."
Verdict Logic
while the company maintains a healthy current ratio of 18.51, the persistent quarterly cash burn of $18.4 million and lack of revenue visibility suggest that the stock remains a speculative play on clinical trial success.
TECX Growth Metrics
Tectonic Therapeutic, Inc. (TECX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-42.3%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM38.99%
Return on Capital
10 Years-116.06%
5 Years-93.78%
3 Years-120.5%
Last Year-42.8%
TECX Recent Earnings
Tectonic Therapeutic, Inc. (TECX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.34-15.5%
$1.16
Rev
—
—
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$1.03+7.2%
$1.11
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.02+2.9%
$1.05
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.07-9.2%
$0.98
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.34vs $1.16-15.5% | — |
| Q1 2026 | Feb 26, 2026 | $1.03vs $1.11+7.2% | — |
| Q4 2025 | Nov 6, 2025 | $1.02vs $1.05+2.9% | — |
| Q3 2025 | Aug 7, 2025 | $1.07vs $0.98-9.2% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Tectonic Therapeutic, Inc. (TECX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $31.99 | $603.63M | -7.90 | — | — | -37.82% | — | |
| $31.00 | $3.12B | -9.42 | -4.26% | -156.36% | -68.97% | — | |
| $27.00 | $3.38B | -207.69 | 91.34% | -0.57% | -1.41% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $10.02 | $524.58M | -2.21 | -92.84% | -260.92% | -49.88% | — |
Compare TECX vs Peers
Tectonic Therapeutic, Inc. (TECX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TECX SEC Filings & Documents
Tectonic Therapeutic, Inc. (TECX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when TECX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TECX Frequently Asked Questions
Tectonic Therapeutic, Inc. (TECX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is TECX profitable?
Tectonic Therapeutic, Inc. (TECX) reported a net loss of $83.5M for fiscal year 2025.
Dividend & Returns
What is TECX's return on equity?
Tectonic Therapeutic, Inc. (TECX) has a return on equity (ROE) of -37.8%. Negative ROE indicates the company is unprofitable.
What is Tectonic Therapeutic, Inc.'s free cash flow?
Tectonic Therapeutic, Inc. (TECX) had negative free cash flow of $65.7M in fiscal year 2025, likely due to heavy capital investments.